Transitioning peanut oral immunotherapy to clinical practice

Area of Science:

• Allergy and Immunology
• Pediatric Allergy
• Clinical Nutrition

Background:

• Peanut allergy prevalence is increasing globally, particularly in industrialized nations, affecting 1%-4.5% of children.
• Peanut allergy poses significant risks, including severe anaphylaxis and food allergy-induced mortality, and severely impacts patients' quality of life.
• Current management involves strict avoidance and carries risks, leading to significant patient and family burden.

Purpose of the Study:

• To evaluate oral immunotherapy (OIT) as a viable treatment for IgE-mediated peanut allergy.
• To assess the efficacy and safety profile of OIT in peanut-allergic patients, especially children.
• To highlight the importance of shared decision-making in initiating OIT.

Main Methods:

• Review of randomized controlled trials and real-world studies on peanut OIT.
• Analysis of desensitization rates and safety data from OIT interventions.
• Examination of factors influencing treatment decisions for peanut allergy.

Main Results:

• Oral immunotherapy demonstrates high rates of successful desensitization in peanut-allergic individuals.
• OIT exhibits a favorable safety profile, particularly when administered to young children.
• Studies confirm OIT's potential to improve clinical outcomes and reduce allergic reactions.

Conclusions:

• Oral immunotherapy is an established and effective treatment for IgE-mediated peanut allergy.
• Shared decision-making, incorporating patient-centered, evidence-based discussions, is crucial for initiating OIT.
• OIT offers a promising therapeutic avenue to mitigate the impact of peanut allergy on patients and families.